Allogene Therapeutics, Inc.
RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
Last updated:
Abstract:
Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.
Status:
Application
Type:
Utility
Filling date:
24 Apr 2020
Issue date:
10 Dec 2020